Catalent Inc (CTLT) Stock Fundamental Analysis

USA New York Stock Exchange NYSE:CTLT • US1488061029

63.48 USD
0 (0%)
At close: Dec 17, 2024
63.5 USD
+0.02 (+0.03%)
After Hours: 12/17/2024, 8:52:12 PM
Fundamental Rating

3

CTLT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of CTLT have multiple concerns. CTLT is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year CTLT was profitable.
  • In the past year CTLT had a positive cash flow from operations.
  • In multiple years CTLT reported negative net income over the last 5 years.
  • CTLT had a positive operating cash flow in each of the past 5 years.
CTLT Yearly Net Income VS EBIT VS OCF VS FCFCTLT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M -1B

1.2 Ratios

  • The Return On Assets of CTLT (-4.25%) is better than 78.01% of its industry peers.
  • CTLT has a better Return On Equity (-11.66%) than 75.92% of its industry peers.
Industry RankSector Rank
ROA -4.25%
ROE -11.66%
ROIC N/A
ROA(3y)-2.82%
ROA(5y)-0.09%
ROE(3y)-8.14%
ROE(5y)-1.42%
ROIC(3y)N/A
ROIC(5y)N/A
CTLT Yearly ROA, ROE, ROICCTLT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

  • CTLT has a Gross Margin of 21.82%. This is comparable to the rest of the industry: CTLT outperforms 51.83% of its industry peers.
  • CTLT's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for CTLT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 21.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.68%
GM growth 5Y-7.41%
CTLT Yearly Profit, Operating, Gross MarginsCTLT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20 30

3

2. Health

2.1 Basic Checks

  • CTLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CTLT has more shares outstanding
  • Compared to 5 years ago, CTLT has more shares outstanding
  • CTLT has a worse debt/assets ratio than last year.
CTLT Yearly Shares OutstandingCTLT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
CTLT Yearly Total Debt VS Total AssetsCTLT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

  • Based on the Altman-Z score of 1.62, we must say that CTLT is in the distress zone and has some risk of bankruptcy.
  • CTLT has a better Altman-Z score (1.62) than 64.92% of its industry peers.
  • CTLT has a debt to FCF ratio of 49.84. This is a negative value and a sign of low solvency as CTLT would need 49.84 years to pay back of all of its debts.
  • CTLT has a Debt to FCF ratio of 49.84. This is in the better half of the industry: CTLT outperforms 78.01% of its industry peers.
  • A Debt/Equity ratio of 1.38 is on the high side and indicates that CTLT has dependencies on debt financing.
  • CTLT has a Debt to Equity ratio of 1.38. This is in the lower half of the industry: CTLT underperforms 74.87% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.38
Debt/FCF 49.84
Altman-Z 1.62
ROIC/WACCN/A
WACC9.31%
CTLT Yearly LT Debt VS Equity VS FCFCTLT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

2.3 Liquidity

  • A Current Ratio of 2.51 indicates that CTLT has no problem at all paying its short term obligations.
  • CTLT has a Current ratio (2.51) which is comparable to the rest of the industry.
  • CTLT has a Quick Ratio of 1.93. This is a normal value and indicates that CTLT is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.93, CTLT is in line with its industry, outperforming 44.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.51
Quick Ratio 1.93
CTLT Yearly Current Assets VS Current LiabilitesCTLT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

4

3. Growth

3.1 Past

  • The earnings per share for CTLT have decreased strongly by -61.40% in the last year.
  • The earnings per share for CTLT have been decreasing by -33.48% on average. This is quite bad
  • Looking at the last year, CTLT shows a small growth in Revenue. The Revenue has grown by 4.71% in the last year.
  • The Revenue has been growing by 11.71% on average over the past years. This is quite good.
EPS 1Y (TTM)-61.4%
EPS 3Y-56.51%
EPS 5Y-33.48%
EPS Q2Q%-30%
Revenue 1Y (TTM)4.71%
Revenue growth 3Y3.1%
Revenue growth 5Y11.71%
Sales Q2Q%4.18%

3.2 Future

  • CTLT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 73.38% yearly.
  • The Revenue is expected to grow by 7.44% on average over the next years.
EPS Next Y350.55%
EPS Next 2Y148.11%
EPS Next 3Y113.64%
EPS Next 5Y73.38%
Revenue Next Year8.33%
Revenue Next 2Y8.2%
Revenue Next 3Y8.33%
Revenue Next 5Y7.44%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CTLT Yearly Revenue VS EstimatesCTLT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2B 4B 6B
CTLT Yearly EPS VS EstimatesCTLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1 2 3 4 5

4

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 288.55, the valuation of CTLT can be described as expensive.
  • CTLT's Price/Earnings ratio is a bit cheaper when compared to the industry. CTLT is cheaper than 78.01% of the companies in the same industry.
  • CTLT is valuated expensively when we compare the Price/Earnings ratio to 27.67, which is the current average of the S&P500 Index.
  • CTLT is valuated quite expensively with a Price/Forward Earnings ratio of 41.25.
  • CTLT's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CTLT is cheaper than 76.44% of the companies in the same industry.
  • CTLT is valuated expensively when we compare the Price/Forward Earnings ratio to 27.20, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 288.55
Fwd PE 41.25
CTLT Price Earnings VS Forward Price EarningsCTLT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150 200 250

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CTLT is valued a bit cheaper than 76.96% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, CTLT is valued a bit cheaper than 78.53% of the companies in the same industry.
Industry RankSector Rank
P/FCF 116.39
EV/EBITDA 36.47
CTLT Per share dataCTLT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • CTLT's earnings are expected to grow with 113.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.82
PEG (5Y)N/A
EPS Next 2Y148.11%
EPS Next 3Y113.64%

0

5. Dividend

5.1 Amount

  • No dividends for CTLT!.
Industry RankSector Rank
Dividend Yield N/A

Catalent Inc

NYSE:CTLT (12/17/2024, 8:52:12 PM)

After market: 63.5 +0.02 (+0.03%)

63.48

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05
Earnings (Next)02-07
Inst Owners92.2%
Inst Owner Change0%
Ins Owners0.48%
Ins Owner Change0%
Market Cap11.52B
Revenue(TTM)4.42B
Net Income(TTM)-413.00M
Analysts52.86
Price Target64.77 (2.03%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-149.78%
Min EPS beat(2)-336.02%
Max EPS beat(2)36.46%
EPS beat(4)1
Avg EPS beat(4)-365.14%
Min EPS beat(4)-1032.86%
Max EPS beat(4)36.46%
EPS beat(8)2
Avg EPS beat(8)-208.81%
EPS beat(12)5
Avg EPS beat(12)-141.22%
EPS beat(16)9
Avg EPS beat(16)-103.51%
Revenue beat(2)1
Avg Revenue beat(2)-0.51%
Min Revenue beat(2)-5.19%
Max Revenue beat(2)4.16%
Revenue beat(4)1
Avg Revenue beat(4)-1.79%
Min Revenue beat(4)-6.04%
Max Revenue beat(4)4.16%
Revenue beat(8)4
Avg Revenue beat(8)0.21%
Revenue beat(12)6
Avg Revenue beat(12)-0.33%
Revenue beat(16)8
Avg Revenue beat(16)-0.03%
PT rev (1m)0.11%
PT rev (3m)4.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-43.12%
EPS NY rev (1m)4.18%
EPS NY rev (3m)-6.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.9%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-0.69%
Valuation
Industry RankSector Rank
PE 288.55
Fwd PE 41.25
P/S 2.61
P/FCF 116.39
P/OCF 28.88
P/B 3.25
P/tB 31.57
EV/EBITDA 36.47
EPS(TTM)0.22
EY0.35%
EPS(NY)1.54
Fwd EY2.42%
FCF(TTM)0.55
FCFY0.86%
OCF(TTM)2.2
OCFY3.46%
SpS24.36
BVpS19.51
TBVpS2.01
PEG (NY)0.82
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -4.25%
ROE -11.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 21.82%
FCFM 2.24%
ROA(3y)-2.82%
ROA(5y)-0.09%
ROE(3y)-8.14%
ROE(5y)-1.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.68%
GM growth 5Y-7.41%
F-Score5
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 1.38
Debt/FCF 49.84
Debt/EBITDA 11.05
Cap/Depr 61.22%
Cap/Sales 6.78%
Interest Coverage N/A
Cash Conversion 90.27%
Profit Quality N/A
Current Ratio 2.51
Quick Ratio 1.93
Altman-Z 1.62
F-Score5
WACC9.31%
ROIC/WACCN/A
Cap/Depr(3y)125.99%
Cap/Depr(5y)159.79%
Cap/Sales(3y)11.57%
Cap/Sales(5y)13.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-61.4%
EPS 3Y-56.51%
EPS 5Y-33.48%
EPS Q2Q%-30%
EPS Next Y350.55%
EPS Next 2Y148.11%
EPS Next 3Y113.64%
EPS Next 5Y73.38%
Revenue 1Y (TTM)4.71%
Revenue growth 3Y3.1%
Revenue growth 5Y11.71%
Sales Q2Q%4.18%
Revenue Next Year8.33%
Revenue Next 2Y8.2%
Revenue Next 3Y8.33%
Revenue Next 5Y7.44%
EBIT growth 1Y-166.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year196.68%
EBIT Next 3Y58.17%
EBIT Next 5Y41.23%
FCF growth 1Y121.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y116.85%
OCF growth 3Y-14.78%
OCF growth 5Y1.59%

Catalent Inc / CTLT FAQ

What is the ChartMill fundamental rating of Catalent Inc (CTLT) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CTLT.


What is the valuation status of Catalent Inc (CTLT) stock?

ChartMill assigns a valuation rating of 4 / 10 to Catalent Inc (CTLT). This can be considered as Fairly Valued.


Can you provide the profitability details for Catalent Inc?

Catalent Inc (CTLT) has a profitability rating of 3 / 10.


Can you provide the PE and PB ratios for CTLT stock?

The Price/Earnings (PE) ratio for Catalent Inc (CTLT) is 288.55 and the Price/Book (PB) ratio is 3.25.


What is the expected EPS growth for Catalent Inc (CTLT) stock?

The Earnings per Share (EPS) of Catalent Inc (CTLT) is expected to grow by 350.55% in the next year.